EP0642589A4
(en)
*
|
1992-05-11 |
1997-05-21 |
Ribozyme Pharm Inc |
METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US7994295B2
(en)
*
|
1997-12-22 |
2011-08-09 |
The University Of Tennessee Research Corporation |
Recombinant viruses comprising the membrane-proximal domain of VSV G protein
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
CZ295108B6
(cs)
|
1998-03-20 |
2005-05-18 |
Benitec Australia Ltd |
Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
|
US20030228597A1
(en)
*
|
1998-04-13 |
2003-12-11 |
Cowsert Lex M. |
Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
|
CA2326823A1
(en)
*
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
US20060172925A1
(en)
*
|
1998-10-26 |
2006-08-03 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US20040242521A1
(en)
*
|
1999-10-25 |
2004-12-02 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
EP2314700A1
(en)
*
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US6987025B1
(en)
|
1999-02-11 |
2006-01-17 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Dwf4 polynucleotides, polypeptides and uses thereof
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
WO2000063364A2
(en)
*
|
1999-04-21 |
2000-10-26 |
American Home Products Corporation |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
US20040002153A1
(en)
*
|
1999-07-21 |
2004-01-01 |
Monia Brett P. |
Modulation of PTEN expression via oligomeric compounds
|
US6423885B1
(en)
*
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
DE10160151A1
(de)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US20050020525A1
(en)
*
|
2002-02-20 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
US20070026394A1
(en)
*
|
2000-02-11 |
2007-02-01 |
Lawrence Blatt |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20030084471A1
(en)
*
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
EP1272630A2
(en)
*
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
WO2001070949A1
(en)
*
|
2000-03-17 |
2001-09-27 |
Benitec Australia Ltd |
Genetic silencing
|
ES2500923T3
(es)
*
|
2000-03-30 |
2014-10-01 |
The Whitehead Institute For Biomedical Research |
Mediadores específicos de secuencia de ARN de interferencia de ARN
|
ES2336887T5
(es)
*
|
2000-03-30 |
2019-03-06 |
Whitehead Inst Biomedical Res |
Mediadores de interferencia por ARN específicos de secuencias de ARN
|
US7691991B2
(en)
|
2000-04-17 |
2010-04-06 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding cytochrome P450 proteins
|
AU2001284160A1
(en)
*
|
2000-08-19 |
2002-03-04 |
Axordia Limited |
Modulation of stem cell differentiation
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
US20020165192A1
(en)
|
2000-09-19 |
2002-11-07 |
Kerr William G. |
Control of NK cell function and survival by modulation of ship activity
|
EP1666595A1
(en)
|
2000-10-26 |
2006-06-07 |
Beth Israel Deaconess Medical Center, Inc. |
GAB2 (P97) gene and methods of use thereof
|
EP1873259B1
(en)
*
|
2000-12-01 |
2012-01-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
RNA interference mediated by 21 and 22nt RNAs
|
AU2013201799B2
(en)
*
|
2000-12-01 |
2014-08-14 |
Europaisches Laboratorium Fur Molekularbiologie (Embl) |
Rna interference mediating small rna molecules
|
US7385046B2
(en)
|
2001-01-03 |
2008-06-10 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding ethylene responsive element binding proteins
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
CA2369944A1
(en)
|
2001-01-31 |
2002-07-31 |
Nucleonics Inc. |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
JP3765574B2
(ja)
*
|
2001-02-22 |
2006-04-12 |
三菱化学株式会社 |
逆向き反復配列を含む組み換え遺伝子及びその利用
|
US20050176663A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050261219A1
(en)
*
|
2001-05-18 |
2005-11-24 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20060217331A1
(en)
*
|
2001-05-18 |
2006-09-28 |
Sirna Therapeutics, Inc. |
Chemically modified double stranded nucleic acid molecules that mediate RNA interference
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050277133A1
(en)
*
|
2001-05-18 |
2005-12-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20090299045A1
(en)
*
|
2001-05-18 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US7109165B2
(en)
*
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20070093437A1
(en)
*
|
2001-05-18 |
2007-04-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20030124513A1
(en)
*
|
2001-05-29 |
2003-07-03 |
Mcswiggen James |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050048529A1
(en)
*
|
2002-02-20 |
2005-03-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050159381A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
EP1627061B1
(en)
*
|
2001-05-18 |
2009-08-12 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050191618A1
(en)
*
|
2001-05-18 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050171040A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050176025A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050124569A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US20050158735A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
|
WO2004111237A1
(en)
*
|
2003-04-16 |
2004-12-23 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR (ECGF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050196781A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
WO2003001877A2
(en)
*
|
2001-06-26 |
2003-01-09 |
Gene Logic, Inc. |
Methods for the diagnosis and treatment of cardiac tissue rejection
|
KR20040022449A
(ko)
|
2001-07-12 |
2004-03-12 |
유니버시티 오브 매사추세츠 |
유전자 불활성화를 매개하는 소형 간섭 rna의 생체내제조
|
US10590418B2
(en)
*
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
JP2005508306A
(ja)
|
2001-07-23 |
2005-03-31 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
哺乳類における遺伝子発現のRNAiによる阻害に関する方法および組成物
|
US20030198627A1
(en)
*
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
US7745418B2
(en)
*
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
WO2003035870A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung eines pankreaskarzinoms
|
US20050119202A1
(en)
*
|
2001-10-26 |
2005-06-02 |
Roland Kreutzer |
Medicament to treat a fibrotic disease
|
US20040121348A1
(en)
*
|
2001-10-26 |
2004-06-24 |
Ribopharma Ag |
Compositions and methods for treating pancreatic cancer
|
DE10230996A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Behandlung eines Pankreaskarzinoms
|
DE10230997A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
|
CN1604783A
(zh)
*
|
2001-10-26 |
2005-04-06 |
里伯药品公司 |
通过rna干扰治疗纤维化疾病的药物
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
KR20050041999A
(ko)
*
|
2001-11-05 |
2005-05-04 |
얀센 파마슈티카 엔.브이. |
짧은 이중 나선 rna의 인비트로 합성을 위한 방법
|
FR2832154B1
(fr)
|
2001-11-09 |
2007-03-16 |
Centre Nat Rech Scient |
Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
|
JP2005525790A
(ja)
*
|
2001-11-19 |
2005-09-02 |
プロテオロジックス,インク. |
潜在的薬物ターゲットを同定及びバリデートする方法
|
ES2401326T3
(es)
*
|
2001-11-21 |
2013-04-18 |
Astellas Pharma Inc. |
Procedimiento para inhibir la expresión génica
|
US7871619B2
(en)
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US7294504B1
(en)
|
2001-12-27 |
2007-11-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
Methods and compositions for DNA mediated gene silencing
|
AU2003237616B2
(en)
|
2002-01-17 |
2007-07-05 |
The University Of British Columbia |
Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
|
DE10202419A1
(de)
*
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
ATE508188T1
(de)
|
2002-02-01 |
2011-05-15 |
Life Technologies Corp |
Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
|
WO2003064621A2
(en)
|
2002-02-01 |
2003-08-07 |
Ambion, Inc. |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
US7820632B2
(en)
|
2002-02-14 |
2010-10-26 |
City Of Hope |
Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
|
US20090099117A1
(en)
*
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
JP2005517427A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるC型肝炎ウイルス(HCV)遺伝子発現のRNA干渉媒介性阻害
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US8067575B2
(en)
*
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050004008A1
(en)
*
|
2002-03-01 |
2005-01-06 |
Frackelton A. Raymond |
SHC proteins as therapeutic targets in proliferative diseases
|
US7129267B2
(en)
|
2002-03-11 |
2006-10-31 |
Janssen Pharmaceutica N.V. |
Methods for SHP1 mediated neuroprotection
|
JP2005521393A
(ja)
*
|
2002-03-20 |
2005-07-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
Hiv治療
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US7541150B2
(en)
|
2002-04-08 |
2009-06-02 |
University Of Louisville Research Foundation, Inc |
Method for the diagnosis and prognosis of malignant diseases
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
US20050222061A1
(en)
*
|
2002-04-18 |
2005-10-06 |
Schulte Ralf W |
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
PT1504126E
(pt)
|
2002-05-03 |
2014-06-02 |
Univ Duke |
Um método para regular a expressão génica
|
AU2003234336A1
(en)
*
|
2002-05-03 |
2003-11-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for use in preparing sirnas
|
AU2003239897A1
(en)
|
2002-05-23 |
2003-12-12 |
Ceptyr, Inc. |
Modulation of ptp1b signal transduction by rna interference
|
WO2003099298A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference mediating small rna molecules
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20050221326A1
(en)
*
|
2002-06-12 |
2005-10-06 |
Avi Orr-Urtreger |
Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
AU2003276666A1
(en)
*
|
2002-06-12 |
2003-12-31 |
Ambion, Inc. |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
AU2003242688A1
(en)
*
|
2002-06-20 |
2004-01-06 |
Dsm Ip Assets B.V. |
Inhibition of nuclear receptors
|
US20040086911A1
(en)
*
|
2002-06-24 |
2004-05-06 |
Baylor College Of Medicine |
Inhibition of gene expression in vertebrates using double-stranded RNA (RNAi)
|
WO2004003179A1
(en)
|
2002-06-27 |
2004-01-08 |
The University Of Queensland |
Differentiation modulating agents and uses therefor
|
CA2491164C
(en)
|
2002-06-28 |
2012-05-08 |
Cory Giesbrecht |
Method and apparatus for producing liposomes
|
DE10229872A1
(de)
*
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
BRPI0312818B8
(pt)
|
2002-07-19 |
2021-05-25 |
Beth Israel Deaconess Medical Ct Inc |
uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
|
US7435419B2
(en)
|
2002-07-19 |
2008-10-14 |
Beth Israel Deaconess Medical Center |
Methods of diagnosing and treating pre-eclampsia or eclampsia
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7399851B2
(en)
|
2002-07-25 |
2008-07-15 |
Dana Farber Cancer Institute, Inc. |
Composition and method for imaging cells
|
AU2003261231A1
(en)
*
|
2002-07-26 |
2004-02-16 |
Chiron Corporation |
Modified small interfering rna molecules and methods of use
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20050106731A1
(en)
*
|
2002-08-05 |
2005-05-19 |
Davidson Beverly L. |
siRNA-mediated gene silencing with viral vectors
|
ES2695050T3
(es)
*
|
2002-08-05 |
2018-12-28 |
Silence Therapeutics Gmbh |
Nuevas formas adicionales de moléculas de ARN de interferencia
|
US20050255086A1
(en)
*
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20080176812A1
(en)
*
|
2002-08-05 |
2008-07-24 |
Davidson Beverly L |
Allele-specific silencing of disease genes
|
ES2389024T3
(es)
*
|
2002-08-05 |
2012-10-22 |
Silence Therapeutics Aktiengesellschaft |
Moléculas de RNA interferentes de extremos romos
|
US20080274989A1
(en)
*
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20040023390A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
EP1527176B2
(en)
|
2002-08-05 |
2017-03-22 |
Silence Therapeutics GmbH |
Further novel forms of interfering rna molecules
|
EP1546173A4
(en)
*
|
2002-08-06 |
2006-05-31 |
Intradigm Corp |
METHODS OF INVIVO TARGET GENE EXPRESSION REDUCTION BY INTRODUCTION OF INTERFERING RNA
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
WO2004015062A2
(en)
|
2002-08-12 |
2004-02-19 |
New England Biolabs, Inc. |
Methods and compositions relating to gene silencing
|
EP1393742A1
(en)
|
2002-08-14 |
2004-03-03 |
atugen AG |
Use of protein kinase N beta
|
PT1536827E
(pt)
|
2002-08-14 |
2009-03-20 |
Silence Therapeutics Ag |
Utilização de proteína cinase n beta
|
JP4717633B2
(ja)
|
2002-08-21 |
2011-07-06 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
癌関連タンパク質を標的とするRNAiプローブ
|
AU2003298574B2
(en)
|
2002-09-05 |
2008-04-24 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7655772B2
(en)
|
2002-09-06 |
2010-02-02 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US8071560B2
(en)
|
2004-02-17 |
2011-12-06 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
US20050272650A1
(en)
|
2004-02-17 |
2005-12-08 |
Mohapatra Shyam S |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
US20040053289A1
(en)
*
|
2002-09-09 |
2004-03-18 |
The Regents Of The University Of California |
Short interfering nucleic acid hybrids and methods thereof
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
CN1694959B
(zh)
|
2002-09-13 |
2013-09-18 |
雷普利瑟公司 |
非序列互补的抗病毒寡核苷酸
|
US20090217404A1
(en)
*
|
2002-09-27 |
2009-08-27 |
Lowe Scott W |
Cell-based RNA interference and related methods and compositions
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
CA2500468A1
(en)
*
|
2002-09-28 |
2004-04-08 |
Massachussets Institute Of Technology |
Influenza therapeutic
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
US7122361B2
(en)
|
2002-10-10 |
2006-10-17 |
Wyeth |
Compositions employing a novel human kinase
|
US20040077082A1
(en)
*
|
2002-10-18 |
2004-04-22 |
Koehn Richard K. |
RNA-based inhibitory oligonucleotides
|
DE60325754D1
(de)
|
2002-10-18 |
2009-02-26 |
Silence Therapeutics Ag |
An der metastase beteiligter faktor und verwendungen dafür
|
WO2004038026A2
(en)
|
2002-10-24 |
2004-05-06 |
Wyeth |
Calcineurin-like human phosphoesterase
|
EP1581654A4
(en)
*
|
2002-10-28 |
2007-01-03 |
Invitrogen Corp |
SYNTHESIS AND USE OF MATRIX OLIGOMERS
|
NZ540779A
(en)
|
2002-11-01 |
2008-05-30 |
Univ Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
EP1560839A4
(en)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
CHIMERIC OLIGOMER COMPOUNDS AND THEIR USE IN GENE MODULATION
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US7696345B2
(en)
|
2002-11-05 |
2010-04-13 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
US9827263B2
(en)
|
2002-11-05 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
CN1498964A
(zh)
*
|
2002-11-07 |
2004-05-26 |
本元正阳基因技术股份有限公司 |
可诱导RNAi途径的用于基因治疗的系列重组腺相关病毒
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7906326B2
(en)
|
2003-05-07 |
2011-03-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US8198427B1
(en)
*
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
PT2284266E
(pt)
*
|
2002-11-14 |
2013-12-17 |
Thermo Fisher Scient Biosciences Inc |
Siarn contra tp53
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
US7064337B2
(en)
|
2002-11-19 |
2006-06-20 |
The Regents Of The University Of California |
Radiation detection system for portable gamma-ray spectroscopy
|
AU2003298689A1
(en)
|
2002-11-21 |
2004-06-18 |
Wyeth |
Methods for diagnosing rcc and other solid tumors
|
US20040191905A1
(en)
*
|
2002-11-22 |
2004-09-30 |
University Of Massachusetts |
Modulation of HIV replication by RNA interference
|
JP4526228B2
(ja)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
RNAiによる新規治療法および治療剤
|
EP2112229A3
(en)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Methods for identifying risk of breast cancer and treatments thereof
|
US7696334B1
(en)
|
2002-12-05 |
2010-04-13 |
Rosetta Genomics, Ltd. |
Bioinformatically detectable human herpesvirus 5 regulatory gene
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
US20130130231A1
(en)
|
2002-11-26 |
2013-05-23 |
Isaac Bentwich |
Bioinformatically detectable group of novel viral regulatory genes and uses thereof
|
WO2004050831A2
(en)
|
2002-11-27 |
2004-06-17 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
US20040110698A1
(en)
*
|
2002-12-10 |
2004-06-10 |
Kimron Veterinary Institute |
Oligonucleotides and methods using same for treating cox-ll associated diseases
|
WO2004063342A2
(en)
*
|
2003-01-09 |
2004-07-29 |
Invitrogen Corporation |
Cellular delivery and activation polypeptide-nucleic acid complexes
|
CA2513623A1
(en)
|
2003-01-16 |
2004-08-05 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for sirna inhibition of icam-1
|
US20070104688A1
(en)
*
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
US20040171118A1
(en)
*
|
2003-02-13 |
2004-09-02 |
City Of Hope |
Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
|
US20090186839A1
(en)
*
|
2003-02-17 |
2009-07-23 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in chemoresistance
|
EP1599573B1
(en)
*
|
2003-02-17 |
2013-06-19 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in tumor resistance to chemotherapy
|
US7521534B1
(en)
|
2003-03-03 |
2009-04-21 |
The University Board Of Regents Of Texas System |
IKK gamma gene products and methods for making and using same
|
KR20050098954A
(ko)
*
|
2003-03-05 |
2005-10-12 |
세네스코 테크놀로지스 인코포레이티드 |
이아이에프-5에이1의 발현을 억제하기 위한 안티센스올리고뉴클레오타이드 또는 에스아이알엔에이의 이용
|
EP3450559A1
(en)
|
2003-03-07 |
2019-03-06 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
GB0306715D0
(en)
*
|
2003-03-24 |
2003-04-30 |
Novartis Ag |
Organic compounds
|
US20070197457A1
(en)
|
2003-04-01 |
2007-08-23 |
Dan Gazit |
Tak1-mediated inhibition of osteogenesis
|
JP4912873B2
(ja)
*
|
2003-04-09 |
2012-04-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
iRNA複合体
|
CA2521464C
(en)
|
2003-04-09 |
2013-02-05 |
Alnylam Pharmaceuticals, Inc. |
Irna conjugates
|
WO2004092383A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8017762B2
(en)
|
2003-04-17 |
2011-09-13 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
US7723509B2
(en)
|
2003-04-17 |
2010-05-25 |
Alnylam Pharmaceuticals |
IRNA agents with biocleavable tethers
|
DK1620544T3
(en)
|
2003-04-17 |
2019-01-14 |
Alnylam Pharmaceuticals Inc |
MODIFIED iRNA AGENTS
|
AU2013205519B2
(en)
*
|
2003-04-17 |
2015-07-16 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
EP1625138A4
(en)
|
2003-04-17 |
2010-06-23 |
Alnylam Pharmaceuticals Inc |
PROTECTED MONOMERS
|
US7851615B2
(en)
|
2003-04-17 |
2010-12-14 |
Alnylam Pharmaceuticals, Inc. |
Lipophilic conjugated iRNA agents
|
US8796436B2
(en)
|
2003-04-17 |
2014-08-05 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
AU2004233043A1
(en)
*
|
2003-04-18 |
2004-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
|
ATE516047T1
(de)
|
2003-05-09 |
2011-07-15 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und anwendungsverfahren
|
AU2003902253A0
(en)
|
2003-05-12 |
2003-05-29 |
The University Of Queensland |
Method for increasing product yield
|
US8609830B2
(en)
*
|
2003-05-16 |
2013-12-17 |
Merck Sharp & Dohme Corp. |
Methods and compositions for RNA interference
|
WO2004106515A1
(ja)
|
2003-05-28 |
2004-12-09 |
Scimedia Ltd. |
抗bambi抗体、及びそれを含有する大腸癌及び肝臓癌の診断剤又は治療剤
|
EP1640452A4
(en)
|
2003-05-30 |
2009-12-23 |
Nippon Shinyaku Co Ltd |
OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
|
ES2357116T5
(es)
*
|
2003-06-02 |
2021-09-03 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y especificad de FNAi
|
DK1633767T3
(en)
*
|
2003-06-02 |
2019-03-25 |
Univ Massachusetts |
METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
CA2524495A1
(en)
|
2003-06-03 |
2005-01-13 |
Eli Lilly And Company |
Modulation of survivin expression
|
NZ543815A
(en)
*
|
2003-06-03 |
2008-08-29 |
Benitec Australia Ltd |
Double-stranded nucleic acid
|
MXPA05013188A
(es)
|
2003-06-06 |
2007-01-30 |
Arborgen Llc |
Composiciones y metodos para regular polisacaridos de una celula vegetal.
|
BRPI0411219A
(pt)
*
|
2003-06-12 |
2006-07-18 |
Nucleonics Inc |
seqüências de hbv e hcv conservadas úteis para silenciamento de gene
|
US8575327B2
(en)
|
2003-06-12 |
2013-11-05 |
Alnylam Pharmaceuticals, Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
WO2005001062A2
(en)
*
|
2003-06-25 |
2005-01-06 |
Gencia Corporation |
Modified vectors for organelle transfection
|
FR2857013B1
(fr)
*
|
2003-07-02 |
2005-09-30 |
Commissariat Energie Atomique |
Petits arn interferents specifiques des sous-unites alpha, alpha prime et beta de la proteine kinase ck2 et leurs applications
|
EP1692153A4
(en)
*
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
CA2532228C
(en)
*
|
2003-07-16 |
2017-02-14 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
US20050026290A1
(en)
*
|
2003-08-01 |
2005-02-03 |
Ciardi Joseph Anthony |
Inhibiting gene expression with dsRNA
|
WO2005047505A2
(en)
|
2003-08-07 |
2005-05-26 |
Whitehead Institute For Biomedical Research |
Methods and products for expression of micro rnas
|
US7888497B2
(en)
*
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
US7825235B2
(en)
*
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
NZ545360A
(en)
|
2003-08-28 |
2009-06-26 |
Novartis Ag |
Interfering RNA duplex having blunt-ends and 3'-modifications
|
EP1670924A1
(en)
*
|
2003-08-28 |
2006-06-21 |
Aveo Pharmaceuticals, Inc. |
Tumor-specific expression of reporter genes
|
ES2808561T3
(es)
*
|
2003-09-12 |
2021-03-01 |
Univ Massachusetts |
Interferencia por ARN para el tratamiento de trastornos de ganancia de función
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
AU2004276823A1
(en)
*
|
2003-09-22 |
2005-04-07 |
Merck And Co., Inc |
Synthetic lethal screen using RNA interference
|
US20050282168A1
(en)
*
|
2003-09-29 |
2005-12-22 |
Wyeth |
Cell surface molecules as markers and therapeutic agents against kidney cancers
|
US20050120415A1
(en)
*
|
2003-10-09 |
2005-06-02 |
E.I. Du Pont De Nemours And Company |
Gene silencing
|
US8507277B2
(en)
*
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
CA2543257C
(en)
*
|
2003-10-24 |
2013-12-31 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8062891B2
(en)
*
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
CA2543954C
(en)
|
2003-10-27 |
2016-11-08 |
Rosetta Inpharmatics Llc |
Method of designing sirnas for gene silencing
|
US20070083943A1
(en)
*
|
2003-10-31 |
2007-04-12 |
Hannah L C |
Materials and methods for improved sweet corn
|
DE10351149A1
(de)
*
|
2003-11-03 |
2005-06-30 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von unerwünschter Pigmentierung der Haut und der Haare durch RNA-Interferenz
|
EP1694842B1
(en)
|
2003-11-04 |
2011-03-23 |
Geron Corporation |
Rna amidates and thioamidates for rnai
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
WO2005081714A2
(en)
|
2003-11-21 |
2005-09-09 |
Revivicor, Inc. |
Use of interfering rna in the production of transgenic animals
|
WO2005059157A2
(en)
*
|
2003-12-11 |
2005-06-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR USE IN PREPARING HAIRPIN RNAs
|
WO2005068630A1
(ja)
*
|
2003-12-16 |
2005-07-28 |
National Institute Of Advanced Industrial Science And Technology |
干渉用二重鎖rna
|
WO2005062937A2
(en)
*
|
2003-12-22 |
2005-07-14 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
|
US20060134787A1
(en)
*
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
AR047574A1
(es)
|
2003-12-30 |
2006-01-25 |
Arborgen Llc 2 Genesis Res 1 |
Genes del ciclo celular y metodos de uso relacionados
|
EP1742661A2
(en)
*
|
2004-01-07 |
2007-01-17 |
Neopharm, Inc. |
Lipid compositions and use thereof
|
US7695964B2
(en)
|
2004-01-23 |
2010-04-13 |
New England Biolabs, Inc. |
Compositions and methods for generating short double-stranded RNA using mutated RNAse III
|
EP2330111A3
(en)
*
|
2004-01-30 |
2011-08-17 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
WO2005073378A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Santaris Pharma A/S |
MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
|
CA2555145A1
(en)
|
2004-02-06 |
2005-08-25 |
Wyeth |
Diagnosis and therapeutics for cancer
|
CA2554818A1
(en)
|
2004-02-09 |
2005-08-25 |
Thomas Jefferson University |
Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
|
CA2554212A1
(en)
*
|
2004-02-10 |
2005-08-25 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
WO2005079299A2
(en)
*
|
2004-02-12 |
2005-09-01 |
New England Biolabs, Inc. |
HIGHLY POTENT hsiRNA MIXTURES AND METHODS FOR GENE SILENCING
|
WO2005079397A2
(en)
*
|
2004-02-13 |
2005-09-01 |
Rockefeller University |
Anti-microrna oligonucleotide molecules
|
US20050182005A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Tuschl Thomas H. |
Anti-microRNA oligonucleotide molecules
|
US20060069050A1
(en)
*
|
2004-02-17 |
2006-03-30 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
US20050273868A1
(en)
*
|
2004-02-17 |
2005-12-08 |
University Of Massachusetts |
Methods and compositions for enhancing RISC activity in vitro and in vivo
|
US7622301B2
(en)
*
|
2004-02-24 |
2009-11-24 |
Basf Plant Science Gmbh |
Compositions and methods using RNA interference for control of nematodes
|
WO2005082415A2
(en)
|
2004-02-25 |
2005-09-09 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
|
AU2005222965B8
(en)
|
2004-03-15 |
2010-07-01 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
JP5184077B2
(ja)
|
2004-03-26 |
2013-04-17 |
キュリス,インコーポレイテッド |
ヘッジホッグシグナリングのrna干渉モジュレーター及びその利用
|
EP2540734B1
(en)
|
2004-04-05 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US8088902B2
(en)
*
|
2004-04-05 |
2012-01-03 |
The Rockefeller University |
DNA virus microRNA and methods for inhibiting same
|
US7416842B2
(en)
*
|
2004-04-05 |
2008-08-26 |
The Rockefeller University |
DNA virus microRNA
|
US7365058B2
(en)
|
2004-04-13 |
2008-04-29 |
The Rockefeller University |
MicroRNA and methods for inhibiting same
|
CA2557532A1
(en)
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition of hairless protein mrna
|
EP1740607A2
(en)
|
2004-04-23 |
2007-01-10 |
Ceres, Inc. |
Methods for modifying plant characteristics
|
JP4584986B2
(ja)
*
|
2004-04-27 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
2−アリールプロピル部分を含む1本鎖及び2本鎖オリゴヌクレオチド
|
US7674778B2
(en)
*
|
2004-04-30 |
2010-03-09 |
Alnylam Pharmaceuticals |
Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
JP5697297B2
(ja)
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロnasおよびその使用
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US7795419B2
(en)
|
2004-05-26 |
2010-09-14 |
Rosetta Genomics Ltd. |
Viral and viral associated miRNAs and uses thereof
|
EP1771563A2
(en)
|
2004-05-28 |
2007-04-11 |
Ambion, Inc. |
METHODS AND COMPOSITIONS INVOLVING MicroRNA
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US20140371299A1
(en)
*
|
2004-06-07 |
2014-12-18 |
Senesco Technologies, Inc. |
Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
|
JP2008504840A
(ja)
*
|
2004-06-30 |
2008-02-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
非リン酸骨格結合を含むオリゴヌクレオチド
|
US7297786B2
(en)
|
2004-07-09 |
2007-11-20 |
University Of Iowa Research Foundation |
RNA interference in respiratory epitheial cells
|
US8361976B2
(en)
|
2004-07-09 |
2013-01-29 |
University Of Massachusetts |
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
|
US7968762B2
(en)
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US7456151B2
(en)
|
2004-07-14 |
2008-11-25 |
University Of Utah Research Foundation |
Promoting angiogenesis with netrin1 polypeptides
|
JP2008522951A
(ja)
|
2004-07-19 |
2008-07-03 |
ベイラー・カレツジ・オブ・メデイシン |
サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
|
EP1828215A2
(en)
|
2004-07-21 |
2007-09-05 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a modified or non-natural nucleobase
|
CA2579574A1
(en)
|
2004-07-23 |
2007-01-04 |
The University Of North Carolina At Chapel Hill |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
WO2006091233A2
(en)
*
|
2004-07-23 |
2006-08-31 |
Boston Medical Center Corporation |
Cellular delivery of reagents that inhibit gene expression utilizing the anthrax toxin protective antigen (pa)
|
EP1774017B1
(en)
|
2004-07-26 |
2013-05-15 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
CA2574603C
(en)
|
2004-08-04 |
2014-11-04 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
EP2990410A1
(en)
|
2004-08-10 |
2016-03-02 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
WO2006110161A2
(en)
*
|
2004-08-13 |
2006-10-19 |
University Of Delaware |
Method for identification and quantification of short or small rna molecules
|
BRPI0514342A2
(pt)
*
|
2004-08-13 |
2009-10-06 |
Basf Plant Science Gmbh |
molécula de rna de filamento duplo, agrupamento de moléculas de rna de filamento duplo, planta transgênica, e, métodos para controlar a infecção de uma planta por um nematóide parasìtico e para fabricar uma planta transgênica
|
PL1791568T3
(pl)
|
2004-08-16 |
2013-01-31 |
Quark Pharmaceuticals Inc |
Terapeutyczne zastosowania inhibitorów RTP801
|
US7893197B2
(en)
|
2004-08-25 |
2011-02-22 |
Janssen Pharmaceutica N.V. |
Relaxin-3 chimeric polypeptides and their preparation and use
|
US7323310B2
(en)
*
|
2004-08-31 |
2008-01-29 |
Qiagen North American Holdings, Inc. |
Methods and compositions for RNA amplification and detection using an RNA-dependent RNA-polymerase
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20060059585A1
(en)
|
2004-09-14 |
2006-03-16 |
Boris Jankowski |
Modulating plant sugar levels
|
US20060057590A1
(en)
*
|
2004-09-14 |
2006-03-16 |
Azeddine Si-Ammour |
RNA probes
|
US7595433B2
(en)
|
2004-09-14 |
2009-09-29 |
Ceres, Inc. |
Modulations of amino acid and sugar content in plants
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
US7799906B1
(en)
|
2004-09-22 |
2010-09-21 |
Arborgen, Llc |
Compositions and methods for modulating lignin of a plant
|
JP5270161B2
(ja)
|
2004-09-24 |
2013-08-21 |
ベス イスラエル デアコネス メディカル センター |
妊娠合併症を診断および処置する方法
|
MX2007003795A
(es)
|
2004-09-28 |
2007-07-11 |
Quark Biotech Inc |
Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
|
MX2007004321A
(es)
*
|
2004-10-12 |
2007-06-07 |
Univ Rockefeller |
Micro acidos ribonucleicos.
|
EP2371954A1
(en)
*
|
2004-10-27 |
2011-10-05 |
Schering Corporation |
Compositions and methods for short interfering nucleic acid inhibition of NAv1.8
|
WO2007001448A2
(en)
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
ES2534301T3
(es)
*
|
2004-11-12 |
2015-04-21 |
Asuragen, Inc. |
Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
|
US20060160110A1
(en)
*
|
2004-12-02 |
2006-07-20 |
Takayuki Mizutani |
Methods of designing small interfering RNAs, antisense polynucleotides, and other hybridizing polynucleotides
|
US7517870B2
(en)
|
2004-12-03 |
2009-04-14 |
Fondazione Telethon |
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
|
US7329797B2
(en)
|
2004-12-08 |
2008-02-12 |
Ceres, Inc. |
Modulating plant carbon levels
|
EP1833838A2
(en)
*
|
2004-12-14 |
2007-09-19 |
Applera Corporation, Applied Biosystems Group |
Cationic liposomes comprising a charge neutral compound and a cationic phospholipid
|
BRPI0519657A2
(pt)
|
2004-12-16 |
2009-03-03 |
Ceres Inc |
modulaÇço dos nÍveis de nitrogÊnio em plantas
|
US7335760B2
(en)
|
2004-12-22 |
2008-02-26 |
Ceres, Inc. |
Nucleic acid sequences encoding zinc finger proteins
|
TWI386225B
(zh)
*
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
|
TWI401316B
(zh)
*
|
2004-12-23 |
2013-07-11 |
Alcon Inc |
用於治療青光眼之血清澱粉樣蛋白A的RNAi抑制作用
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
US8852472B2
(en)
|
2004-12-27 |
2014-10-07 |
Silence Therapeutics Gmbh |
Coated lipid complexes and their use
|
WO2006074108A2
(en)
*
|
2004-12-30 |
2006-07-13 |
Hauser Todd M |
Compositions and methods for modulating gene expression using self-protected oligonucleotides
|
US20070014795A1
(en)
*
|
2004-12-30 |
2007-01-18 |
Dhodapkar Madhav V |
Compositions and methods for enhanced dendritic cell maturation and function
|
US8137907B2
(en)
*
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
EP1841793B1
(en)
|
2005-01-07 |
2010-03-31 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US7718625B2
(en)
|
2005-01-27 |
2010-05-18 |
University Of South Florida |
Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
|
TW200639252A
(en)
*
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular hypertension targets
|
WO2006084053A1
(en)
*
|
2005-02-02 |
2006-08-10 |
Achillion Pharmaceuticals, Inc. |
8-n-substituted-2h-isothiazolo[5,4-b]quinolizine-3,4-diones and related compounds as antiinfective agents
|
US8088579B2
(en)
|
2005-02-14 |
2012-01-03 |
University Of Iowa Research Foundation |
Complement factor H for diagnosis of age-related macular degeneration
|
MX2007010922A
(es)
|
2005-03-10 |
2007-10-12 |
Genentech Inc |
Metodos y composiciones para modular la integridad vascular.
|
DE202005004135U1
(de)
*
|
2005-03-11 |
2005-05-19 |
Klocke Verpackungs-Service Gmbh |
Mehrkomponentenverpackung mit Applikator
|
MX2007010608A
(es)
*
|
2005-03-11 |
2007-10-19 |
Alcon Inc |
Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma.
|
GB0505081D0
(en)
*
|
2005-03-14 |
2005-04-20 |
Genomica Sau |
Downregulation of interleukin-12 expression by means of rnai technology
|
US8999943B2
(en)
|
2005-03-14 |
2015-04-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
EP3312196B1
(en)
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
EP2098593B1
(en)
*
|
2005-04-15 |
2011-12-28 |
National University Corporation Tottori University |
hTERT expression regulatory gene
|
US20090203055A1
(en)
*
|
2005-04-18 |
2009-08-13 |
Massachusetts Institute Of Technology |
Compositions and methods for RNA interference with sialidase expression and uses thereof
|
CA2605701C
(en)
|
2005-04-29 |
2015-12-08 |
Rockefeller University |
Human micrornas and methods for inhibiting same
|
WO2006121703A2
(en)
*
|
2005-05-06 |
2006-11-16 |
The Board Of Trustees Of The University Of Illinois |
Mapping new sites for antibiotic action in the ribosome
|
KR100694804B1
(ko)
|
2005-05-18 |
2007-03-14 |
아주대학교산학협력단 |
작은 헤어핀 rna 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법
|
US20070044164A1
(en)
|
2005-05-31 |
2007-02-22 |
Cold Spring Harbor Laboratory |
Methods for producing microRNAs
|
CN101213300B
(zh)
|
2005-06-01 |
2013-01-23 |
聚加转染股份有限公司 |
用于rna干扰的寡核苷酸及其生物学应用
|
WO2006135862A2
(en)
|
2005-06-10 |
2006-12-21 |
Children's Hospital And Research Center At Oakland |
Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity
|
US20100266574A1
(en)
*
|
2005-06-10 |
2010-10-21 |
Orna Mor |
Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
|
US7723110B2
(en)
|
2005-06-17 |
2010-05-25 |
Arborgen, Llc |
Plant cell signaling genes
|
US7868159B2
(en)
|
2005-06-23 |
2011-01-11 |
Baylor College Of Medicine |
Modulation of negative immune regulators and applications for immunotherapy
|
AU2006267841B2
(en)
|
2005-07-07 |
2011-12-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Nucleic acid agents for downregulating H19, and methods of using same
|
EP1907855A4
(en)
*
|
2005-07-12 |
2009-11-11 |
Univ Temple |
GENETIC AND EPIGENETIC MODIFICATIONS IN THE DIAGNOSIS AND TREATMENT OF CANCER
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
WO2007014370A2
(en)
*
|
2005-07-28 |
2007-02-01 |
University Of Delaware |
Small regulatory rnas and methods of use
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
JP2009504782A
(ja)
*
|
2005-08-18 |
2009-02-05 |
アルナイラム ファーマシューティカルズ インコーポレイテッド |
神経疾患を治療するための方法および組成物
|
WO2007026958A1
(ja)
|
2005-09-01 |
2007-03-08 |
Suntory Limited |
トリプトファントランスポーター遺伝子及びその用途
|
EP1762575A1
(en)
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
CN103028120B
(zh)
|
2005-09-12 |
2015-08-12 |
俄亥俄州立大学研究基金会 |
用于诊断或治疗bcl2相关癌症的组合物和方法
|
EP1931789B1
(en)
|
2005-09-20 |
2016-05-04 |
BASF Plant Science GmbH |
Methods for controlling gene expression using ta-siran
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
US7723314B1
(en)
*
|
2005-10-28 |
2010-05-25 |
Transderm, Inc. |
Methods and compositions for treating pachyonychia congenita
|
EP1946117B1
(en)
*
|
2005-11-11 |
2011-08-24 |
Roger Williams Hospital |
P66-shc as predictive marker in cancer treatment
|
WO2007086990A2
(en)
|
2005-11-17 |
2007-08-02 |
Board Of Regents, The University Of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal dna
|
US20090175871A1
(en)
*
|
2005-11-25 |
2009-07-09 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors
|
CN103710429B
(zh)
|
2005-11-29 |
2016-03-30 |
剑桥企业有限公司 |
乳腺癌标志物
|
JP4737531B2
(ja)
|
2005-12-05 |
2011-08-03 |
サントリーホールディングス株式会社 |
形質転換酵母を用いるセラミドの製造方法
|
EP1795596A1
(en)
|
2005-12-08 |
2007-06-13 |
Ganymed Pharmaceuticals AG |
Composition and methods for therapy and diagnosis of cancer
|
US20090317802A1
(en)
*
|
2005-12-09 |
2009-12-24 |
Bhatia Sangeeta N |
Compositions and Methods to Monitor RNA Delivery to Cells
|
US9157066B2
(en)
|
2005-12-13 |
2015-10-13 |
The Trustees Of The University Of Pennsylvania |
Transcriptome transfer produces cellular phenotype conversion
|
DK2602326T3
(en)
|
2005-12-13 |
2018-12-10 |
Univ Pennsylvania |
Methods for transfecting nucleic acids into living cells
|
US10647960B2
(en)
|
2005-12-13 |
2020-05-12 |
The Trustees Of The University Of Pennsylvania |
Transcriptome transfer produces cellular phenotype conversion
|
US9267937B2
(en)
|
2005-12-15 |
2016-02-23 |
Massachusetts Institute Of Technology |
System for screening particles
|
AU2006337093B2
(en)
*
|
2005-12-22 |
2013-03-14 |
Opko Pharmaceuticals, Llc. |
Compositions and methods for regulating complement system
|
KR101317100B1
(ko)
|
2005-12-30 |
2013-10-15 |
에보니크 룀 게엠베하 |
세포-침투성 펩티드로서 유용한 펩티드
|
CN101400361B
(zh)
|
2006-01-05 |
2012-10-17 |
俄亥俄州立大学研究基金会 |
用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
|
AU2007205257B2
(en)
|
2006-01-05 |
2013-07-25 |
The Ohio State University Research Foundation |
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
|
EP2487257B1
(en)
|
2006-01-05 |
2015-07-01 |
The Ohio State University Research Foundation |
MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
|
US20090175930A1
(en)
|
2006-01-11 |
2009-07-09 |
Nobuhiro Yagi |
Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball
|
BRPI0707290A2
(pt)
|
2006-01-17 |
2011-08-16 |
Biolex Therapeutics Inc |
composições e métodos para humanização e otimização de n-glicanas em plantas
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
ES2683846T3
(es)
|
2006-01-20 |
2018-09-28 |
Cell Signaling Technology, Inc. |
ROS quinasa mutante y de translocación en el carcinoma pulmonar no microcítico humano
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
US8222482B2
(en)
|
2006-01-26 |
2012-07-17 |
Ceres, Inc. |
Modulating plant oil levels
|
US20090176977A1
(en)
*
|
2006-01-27 |
2009-07-09 |
Joacim Elmen |
Lna modified phosphorothiolated oligonucleotides
|
ES2550099T3
(es)
|
2006-01-27 |
2015-11-04 |
Biogen Ma Inc. |
Antagonistas del receptor Nogo
|
WO2007095113A2
(en)
|
2006-02-10 |
2007-08-23 |
Massachusetts Institute Of Technology |
Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
|
EP1996618A1
(en)
|
2006-02-24 |
2008-12-03 |
Suntory Limited |
Ammonia transporter gene and use thereof
|
WO2007099694A1
(en)
|
2006-02-24 |
2007-09-07 |
Suntory Limited |
Gene encoding protein responsible for flocculation property of yeast and use thereof
|
BRPI0608595A2
(pt)
|
2006-02-24 |
2017-07-25 |
Suntory Ltd |
Polinecleotídeo, proteína, vetor, levedura, métodos para produzir uma bebida alcoólica, para avaliar uma levedura de teste quanto a sua propriedade de floculação, e para selecionar uma levedura, e, bebida alcoólica
|
US20100286232A1
(en)
|
2006-03-02 |
2010-11-11 |
The Ohio State University |
Microrna expression profile associated with pancreatic cancer
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
FI20060246A0
(fi)
|
2006-03-16 |
2006-03-16 |
Jukka Westermarck |
Uusi kasvua stimuloiva proteiini ja sen käyttö
|
US7985584B2
(en)
|
2006-03-20 |
2011-07-26 |
The Ohio State University Research Foundation |
MicroRNA fingerprints during human megakaryocytopoiesis
|
ATE485517T1
(de)
|
2006-03-22 |
2010-11-15 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid- targets
|
AU2007229161B2
(en)
*
|
2006-03-23 |
2012-07-12 |
Roche Innovation Center Copenhagen A/S |
Small internally segmented interfering RNA
|
FR2898908A1
(fr)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
|
CA2648099C
(en)
|
2006-03-31 |
2012-05-29 |
The Brigham And Women's Hospital, Inc |
System for targeted delivery of therapeutic agents
|
US8524454B2
(en)
|
2006-04-07 |
2013-09-03 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
EP2018873A4
(en)
|
2006-04-07 |
2009-12-09 |
Japan Found Cancer |
PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
ES2561406T3
(es)
|
2006-04-14 |
2016-02-26 |
Cell Signaling Technology, Inc. |
Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
|
WO2007120847A2
(en)
|
2006-04-14 |
2007-10-25 |
Massachusetts Institute Of Technology |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
CN101573141B
(zh)
|
2006-05-15 |
2016-05-04 |
麻省理工学院 |
用于功能性颗粒的聚合物
|
US20090239936A1
(en)
|
2006-05-15 |
2009-09-24 |
Yoshikazu Sugimoto |
Prophylactic and Therapeutic Agent for Cancer
|
WO2007140599A1
(en)
|
2006-06-05 |
2007-12-13 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
EP2026843A4
(en)
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
THERAPEUTIC USES OF RTP801L INHIBITORS
|
EP2029746B1
(en)
*
|
2006-06-12 |
2012-07-04 |
Exegenics, Inc., D/b/a Opko Health, Inc. |
Compositions and methods for sirna inhibition of angiogenesis
|
WO2007150030A2
(en)
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
SG173371A1
(en)
|
2006-07-13 |
2011-08-29 |
Univ Iowa Res Found |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
EP2041317A4
(en)
|
2006-07-13 |
2009-10-14 |
Univ Ohio State Res Found |
METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
|
CN102321626B
(zh)
|
2006-07-21 |
2014-12-10 |
赛伦斯治疗有限公司 |
用于抑制蛋白激酶3表达的方法
|
AU2007280690C1
(en)
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
WO2008019142A2
(en)
*
|
2006-08-04 |
2008-02-14 |
Massachusetts Institute Of Technology |
Oligonucleotide systems for targeted intracellular delivery
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
JPWO2008032876A1
(ja)
|
2006-09-15 |
2010-01-28 |
学校法人東海大学 |
Er陰性およびher2陰性である乳癌の予防または治療剤およびそのスクリーニング方法
|
CA2663962A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
EP2076599A2
(en)
*
|
2006-09-19 |
2009-07-08 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
EP1911851A1
(en)
|
2006-10-12 |
2008-04-16 |
Ganymed Pharmaceuticals AG |
Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
EP2061901A2
(en)
|
2006-10-31 |
2009-05-27 |
Noxxon Pharma AG |
Methods for detection of a single- or double-stranded nucleic acid molecule
|
ATE508191T1
(de)
|
2006-11-01 |
2011-05-15 |
Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct |
Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase
|
WO2008063933A2
(en)
|
2006-11-10 |
2008-05-29 |
Massachusetts Institute Of Technology |
Pak modulators
|
EP2962697A1
(en)
|
2006-11-27 |
2016-01-06 |
diaDexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP2101813B1
(en)
|
2006-11-27 |
2014-04-02 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
EP2104737B1
(en)
*
|
2006-12-08 |
2013-04-10 |
Asuragen, INC. |
Functions and targets of let-7 micro rnas
|
WO2008073856A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
WO2008073920A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Mir-21 regulated genes and pathways as targets for therapeutic intervention
|
US20090175827A1
(en)
*
|
2006-12-29 |
2009-07-09 |
Byrom Mike W |
miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
US8476243B2
(en)
|
2006-12-29 |
2013-07-02 |
Transderm, Inc. |
Methods and compositions for treating keratin hyperproliferative disorders
|
WO2008091680A2
(en)
|
2007-01-25 |
2008-07-31 |
The General Hospital Corporation |
Methods for controlling stem cell differentiation
|
CA2676143A1
(en)
|
2007-01-26 |
2008-07-31 |
University Of Louisville Research Foundation, Inc. |
Modification of exosomal components for use as a vaccine
|
US8530436B2
(en)
|
2007-01-29 |
2013-09-10 |
Transderm, Inc. |
Methods and compositions for transdermal delivery of nucleotides
|
WO2008098165A2
(en)
|
2007-02-09 |
2008-08-14 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
EP2137205A2
(en)
|
2007-02-26 |
2009-12-30 |
Quark Pharmaceuticals, Inc. |
Inhibitors of rtp801 and their use in disease treatment
|
US20100292301A1
(en)
*
|
2007-02-28 |
2010-11-18 |
Elena Feinstein |
Novel sirna structures
|
AU2008222563A1
(en)
|
2007-03-05 |
2008-09-12 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US20090060889A1
(en)
|
2007-03-12 |
2009-03-05 |
Von Hofe Eric |
Ii-RNAi involved Ii suppression in cancer immunotherapy
|
WO2008115387A2
(en)
*
|
2007-03-15 |
2008-09-25 |
University Hospitals Of Cleveland |
Screening, diagnosing, treating and prognosis of pathophysiologic states by rna regulation
|
CA2680593A1
(en)
*
|
2007-03-19 |
2008-09-25 |
Cold Spring Harbor Laboratory |
Identification of genetic alterations that modulate drug sensitivity in cancer treatments
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
CN101678082B
(zh)
|
2007-03-26 |
2013-06-19 |
再生医药有限公司 |
使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
|
JP5344517B2
(ja)
|
2007-03-30 |
2013-11-20 |
サントリーホールディングス株式会社 |
小胞体局在化シグナル付スフィンゴリピッドδ4−デサチュラーゼを用いた形質転換細胞におけるセラミドの製造方法
|
EP2159281B1
(en)
*
|
2007-03-30 |
2012-09-26 |
National University Corporation Okayama University |
Novel slc17-type transporter protein in mammal and use thereof
|
EP2144600A4
(en)
|
2007-04-04 |
2011-03-16 |
Massachusetts Inst Technology |
POLY (AMINIC ACID) TARGET MOLECULES
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
US20090010941A1
(en)
*
|
2007-04-09 |
2009-01-08 |
University Of Massachusetts |
Methods for treating HIV
|
US7928202B2
(en)
|
2007-04-12 |
2011-04-19 |
The Brigham And Women's Hospital, Inc. |
Targeting ABCB5 for cancer therapy
|
WO2008134461A2
(en)
|
2007-04-27 |
2008-11-06 |
Dow Global Technologies, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
US20080313773A1
(en)
*
|
2007-05-14 |
2008-12-18 |
The Rockefeller University |
Production of artificial micrornas using synthetic microrna precursors
|
PL2162538T3
(pl)
|
2007-05-22 |
2016-10-31 |
|
Oligomery do zastosowań terapeutycznych
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
US8158677B2
(en)
|
2007-06-01 |
2012-04-17 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
WO2008154470A1
(en)
*
|
2007-06-08 |
2008-12-18 |
University Of Connecticut |
Nhibitor of the receptor activity of the s1p2 receptor for inhibiting pathological angiogenesis in the eye
|
US8785408B2
(en)
|
2007-06-27 |
2014-07-22 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for reducing or protecting against delayed graft function (DGF)
|
WO2009005095A1
(ja)
|
2007-07-03 |
2009-01-08 |
Kyorin Pharmaceutical Co., Ltd |
インフルエンザ治療
|
JP2010532989A
(ja)
|
2007-07-10 |
2010-10-21 |
ニューリム ファーマシューティカルズ (1991) リミテッド |
神経変性疾患におけるcd44スプライスバリアント
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
CN101809169B
(zh)
|
2007-07-31 |
2013-07-17 |
俄亥俄州立大学研究基金会 |
通过靶向dnmt3a和dnmt3b恢复甲基化的方法
|
JP5624884B2
(ja)
|
2007-08-02 |
2014-11-12 |
ノビミューンエスアー |
抗rantes抗体およびその使用の方法
|
ES2562077T3
(es)
|
2007-08-03 |
2016-03-02 |
The Ohio State University Research Foundation |
Regiones ultraconservadas que codifican ARNnc
|
CA2697055A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Scott And White Memorial Hospital And Scott, Sherwood And Brindley Found Ation |
Methods and compositions for post-transcriptional gene silencing
|
CN101836112A
(zh)
|
2007-08-22 |
2010-09-15 |
俄亥俄州立大学研究基金会 |
用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
WO2009033140A1
(en)
|
2007-09-06 |
2009-03-12 |
The Ohio State University Research Foundation |
Microrna signatures in human ovarian cancer
|
EP2198050A1
(en)
*
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
DK2548962T3
(en)
|
2007-09-19 |
2016-04-11 |
Applied Biosystems Llc |
Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
|
BRPI0817605A2
(pt)
*
|
2007-10-03 |
2017-05-09 |
Quark Pharmaceuticals Inc |
novas estruturas de sirna
|
AU2008310704B2
(en)
|
2007-10-11 |
2014-03-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
|
EP2620157A3
(en)
|
2007-10-12 |
2013-10-16 |
Massachusetts Institute of Technology |
Vaccine nanotechnology
|
EP3072963B1
(en)
|
2007-10-18 |
2020-04-01 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
EP2060583A1
(en)
|
2007-10-23 |
2009-05-20 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated markers for diagnosis and therapy
|
US8097712B2
(en)
*
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
CN101932339B
(zh)
|
2007-11-30 |
2014-10-29 |
贝勒医学院 |
树突细胞疫苗组合物及其应用
|
WO2009070805A2
(en)
*
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
WO2009073809A2
(en)
*
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
US8507455B2
(en)
*
|
2007-12-04 |
2013-08-13 |
Alnylam Pharmaceuticals, Inc. |
Folate conjugates
|
AU2008336249B2
(en)
|
2007-12-10 |
2015-01-29 |
The University Of Queensland |
Treatment and prophylaxis
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
US20090192114A1
(en)
*
|
2007-12-21 |
2009-07-30 |
Dmitriy Ovcharenko |
miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
KR101483715B1
(ko)
|
2008-01-31 |
2015-01-19 |
큐어백 게엠바하 |
면역증강제/애주번트인 화학식(NuGlXmGnNv)a를 포함하는 핵산 및 이의 유도체
|
EP2260110B1
(en)
*
|
2008-02-08 |
2014-11-12 |
Asuragen, INC. |
miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
EP2268832A2
(en)
*
|
2008-03-06 |
2011-01-05 |
Asuragen, INC. |
Microrna markers for recurrence of colorectal cancer
|
WO2009116037A2
(en)
*
|
2008-03-20 |
2009-09-24 |
Quark Pharmaceuticals, Inc. |
NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
|
EP2271757A2
(en)
*
|
2008-03-26 |
2011-01-12 |
Asuragen, INC. |
Compositions and methods related to mir-16 and therapy of prostate cancer
|
US20090258928A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc. |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
EP2108701A1
(en)
|
2008-04-10 |
2009-10-14 |
Ganymed Pharmaceuticals AG |
Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
EP2285385A4
(en)
*
|
2008-04-15 |
2013-01-16 |
Quark Pharmaceuticals Inc |
COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
|
DK2279254T3
(en)
|
2008-04-15 |
2017-09-18 |
Protiva Biotherapeutics Inc |
PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
|
EP2116602A1
(en)
|
2008-05-07 |
2009-11-11 |
Institut Gustave Roussy |
Combination products for treating cancer
|
EP2990487A1
(en)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
US8222221B2
(en)
|
2008-06-04 |
2012-07-17 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
WO2009147684A2
(en)
|
2008-06-06 |
2009-12-10 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
EP2319519B1
(en)
|
2008-08-01 |
2016-01-27 |
Kyowa Hakko Kirin Co., Ltd. |
Composition for inhibiting expression of target gene
|
US9433684B2
(en)
|
2008-08-19 |
2016-09-06 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
MX2011002143A
(es)
*
|
2008-08-25 |
2011-07-20 |
Excaliard Pharmaceuticals Inc |
Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
|
WO2011028218A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Process for triphosphate oligonucleotide synthesis
|
US20100068200A1
(en)
*
|
2008-09-12 |
2010-03-18 |
The University Of Connecticut |
Methods and Compositions for Inhibiting Atherosclerosis and Vascular Inflammation
|
EP3336188B1
(en)
|
2008-09-22 |
2020-05-06 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering rnai compounds
|
US8962580B2
(en)
|
2008-09-23 |
2015-02-24 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
CA2741664C
(en)
|
2008-10-31 |
2014-12-23 |
Japan Science And Technology Agency |
Method for selective control of helper t cell function
|
EP2727996A1
(en)
|
2008-11-06 |
2014-05-07 |
The Johns-Hopkins University |
Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
|
MX359674B
(es)
|
2008-11-10 |
2018-10-05 |
Alnylam Pharmaceuticals Inc |
Lipidos y composiciones novedosas para el suministro de terapeuticos.
|
WO2010056737A2
(en)
*
|
2008-11-11 |
2010-05-20 |
Mirna Therapeutics, Inc. |
Methods and compositions involving mirnas in cancer stem cells
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
CN104673798B
(zh)
|
2008-12-03 |
2018-03-20 |
阿克丘勒斯治疗公司 |
UsiRNA复合物
|
EP2361306A1
(en)
|
2008-12-04 |
2011-08-31 |
OPKO Ophthalmics, LLC |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
UA109108C2
(uk)
|
2008-12-09 |
2015-07-27 |
Дженентек, Інк. |
Антитіло до pd-l1 та його застосування для посилення функції t-клітин
|
EP2370175A2
(en)
|
2008-12-16 |
2011-10-05 |
Bristol-Myers Squibb Company |
Methods of inhibiting quiescent tumor proliferation
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
JP5592897B2
(ja)
|
2008-12-26 |
2014-09-17 |
サムヤン バイオファーマシューティカルズ コーポレイション |
アニオン性薬物含有薬剤学的組成物及びその製造方法
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
PL2881402T3
(pl)
|
2009-02-12 |
2017-10-31 |
Cell Signaling Technology Inc |
Ekspresja zmutowanej ROS w ludzkim raku wątroby
|
CA2789512A1
(en)
|
2009-02-13 |
2010-08-19 |
Indiana University Research And Technology Corporation |
Compounds and methods for inhibiting mmp2 and mmp9
|
EP2221375A1
(en)
|
2009-02-20 |
2010-08-25 |
Ganymed Pharmaceuticals AG |
Methods and compositions for diagnosis and treatment of cancer
|
US9809815B2
(en)
|
2009-02-20 |
2017-11-07 |
Ganymed Pharmaceuticals Ag |
Methods and compositions for diagnosis and treatment of cancer
|
EP2221063A1
(en)
|
2009-02-20 |
2010-08-25 |
Ganymed Pharmaceuticals AG |
Methods and compositions for diagnosis and treatment of cancer
|
AU2010221419B2
(en)
|
2009-03-02 |
2015-10-01 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
GB2468477A
(en)
|
2009-03-02 |
2010-09-15 |
Mina Therapeutics Ltd |
Double stranded RNA molecule comprising siRNA and miRNA precursors
|
CN102378766A
(zh)
|
2009-03-23 |
2012-03-14 |
夸克医药公司 |
治疗癌症和纤维化疾病的化合物组合物和方法
|
WO2010124231A2
(en)
|
2009-04-24 |
2010-10-28 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
EP2249159A1
(en)
|
2009-04-29 |
2010-11-10 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated markers for diagnosis and therapy
|
US8822426B2
(en)
|
2009-05-05 |
2014-09-02 |
Beeologics Inc. |
Prevention and treatment of nosema disease in bees
|
CN102414320A
(zh)
*
|
2009-05-15 |
2012-04-11 |
贝林格尔.英格海姆国际有限公司 |
具有降低的nocr表达的改良细胞系及其用途
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
ES2804764T3
(es)
|
2009-06-01 |
2021-02-09 |
Halo Bio Rnai Therapeutics Inc |
Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
|
EP2258858A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Transgenic LSD1 animal model for cancer
|
KR102205886B1
(ko)
|
2009-06-10 |
2021-01-21 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
US8268550B2
(en)
|
2009-06-26 |
2012-09-18 |
Massachusetts Institute Of Technology |
Compositions and methods for identification of PARP function, inhibitors, and activators
|
WO2010151664A2
(en)
|
2009-06-26 |
2010-12-29 |
Massachusetts Institute Of Technology |
Compositions and methods for treating cancer and modulating stress granule formation
|
US8435961B2
(en)
|
2009-06-26 |
2013-05-07 |
Massachusetts Institute Of Technology |
Methods and compositions for increasing the activity of inhibitory RNA
|
EP2449114B9
(en)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
ES2629167T3
(es)
|
2009-07-20 |
2017-08-07 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011031600A1
(en)
|
2009-09-10 |
2011-03-17 |
Schering Corporation |
Use of il-33 antagonists to treat fibrotic disease
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
WO2011057171A1
(en)
|
2009-11-08 |
2011-05-12 |
Quark Pharmaceuticals, Inc. |
METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM
|
CA2775373C
(en)
|
2009-11-11 |
2019-10-29 |
Ganymed Pharmaceuticals Ag |
Antibodies specific for claudin 6 (cldn6)
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
AU2010324658A1
(en)
|
2009-11-26 |
2012-05-03 |
Quark Pharmaceuticals, Inc. |
siRNA compounds comprising terminal substitutions
|
JP5077901B2
(ja)
|
2009-11-27 |
2012-11-21 |
独立行政法人科学技術振興機構 |
高脂血症治療剤のスクリーニング方法
|
RU2012127772A
(ru)
*
|
2009-12-04 |
2014-01-10 |
ОПКО ОФТЭЛМИКС, ЭлЭлСи |
Композиции и способы для ингибирования vegf
|
CA2785996C
(en)
|
2009-12-07 |
2021-04-13 |
The Johns Hopkins University |
Sr-bi as a predictor of human female infertility and responsiveness to treatment
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
ES2562499T3
(es)
|
2009-12-09 |
2016-03-04 |
Nitto Denko Corporation |
Modulación de la expresión de HSP47
|
WO2011072091A1
(en)
|
2009-12-09 |
2011-06-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the cns
|
WO2011084357A1
(en)
|
2009-12-17 |
2011-07-14 |
Schering Corporation |
Modulation of pilr to treat immune disorders
|
US20130017223A1
(en)
|
2009-12-18 |
2013-01-17 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
KR101605932B1
(ko)
|
2009-12-18 |
2016-03-24 |
노파르티스 아게 |
Hsf1-관련 질환을 치료하기 위한 유기 조성물
|
US20130023578A1
(en)
|
2009-12-31 |
2013-01-24 |
Samyang Biopharmaceuticals Corporation |
siRNA for inhibition of c-Met expression and anticancer composition containing the same
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
JP2013519869A
(ja)
|
2010-02-10 |
2013-05-30 |
ノバルティス アーゲー |
筋肉成長のための方法および化合物
|
EP2550001B1
(en)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
KR20180044433A
(ko)
|
2010-03-24 |
2018-05-02 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 rna 간섭
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
EP2558115B1
(en)
|
2010-04-16 |
2019-07-31 |
The Salk Institute for Biological Studies |
Methods for treating metabolic disorders using fgf
|
US20130101600A1
(en)
|
2010-04-19 |
2013-04-25 |
Gwendal Lazennec |
Cxcl5 as a marker of hormone escape in prostate cancer
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
KR20220008383A
(ko)
|
2010-04-23 |
2022-01-20 |
애로우헤드 파마슈티컬스 인코포레이티드 |
베타-ENaC-관련 질환을 치료하기 위한 유기 조성물
|
PL2561078T3
(pl)
|
2010-04-23 |
2019-02-28 |
Cold Spring Harbor Laboratory |
Nowe, strukturalnie zaprojektowane shRNA
|
JP5860032B2
(ja)
|
2010-04-28 |
2016-02-16 |
キンバリー クラーク ワールドワイド インコーポレイテッド |
関節リウマチ薬の送達のためのデバイス
|
CA2797205C
(en)
*
|
2010-04-28 |
2019-04-16 |
Kimberly-Clark Worldwide, Inc. |
Medical devices for delivery of sirna
|
JP5868953B2
(ja)
|
2010-04-28 |
2016-02-24 |
キンバリー クラーク ワールドワイド インコーポレイテッド |
射出成形型マイクロニードルアレイ及びその製造方法
|
MX2012012567A
(es)
|
2010-04-28 |
2012-11-21 |
Kimberly Clark Co |
Metodo para aumentar la permeabilidad de una barrera epitelial.
|
EP2566967B1
(en)
|
2010-05-04 |
2016-07-06 |
The Brigham and Women's Hospital, Inc. |
Cadherin-11 antagonist for the treatment of fibrosis
|
AU2011258156B2
(en)
|
2010-05-26 |
2016-11-24 |
Selecta Biosciences, Inc. |
Multivalent synthetic nanocarrier vaccines
|
US20130236968A1
(en)
|
2010-06-21 |
2013-09-12 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
EP2404936A1
(en)
|
2010-07-06 |
2012-01-11 |
Ganymed Pharmaceuticals AG |
Cancer therapy using CLDN6 target-directed antibodies in vivo
|
TW201244719A
(en)
|
2010-07-09 |
2012-11-16 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
EP2955230A1
(en)
|
2010-07-30 |
2015-12-16 |
CureVac AG |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
US20120052079A1
(en)
*
|
2010-08-10 |
2012-03-01 |
Dana-Farber Cancer Institute, Inc. |
Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
EP2622076A1
(en)
|
2010-09-30 |
2013-08-07 |
University of Zürich |
Treatment of b-cell lymphoma with microrna
|
WO2012046065A2
(en)
|
2010-10-06 |
2012-04-12 |
Omnicyte Limited |
Culture method
|
US8916534B2
(en)
|
2010-10-08 |
2014-12-23 |
Mina Therapeutics Limited |
Methods of inducing insulin production
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
WO2012051491A1
(en)
|
2010-10-14 |
2012-04-19 |
The United States Of America, As Represented By The Secretary National Institutes Of Health |
Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
|
WO2012057363A1
(ja)
|
2010-10-27 |
2012-05-03 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
US8569220B2
(en)
|
2010-11-12 |
2013-10-29 |
Jelmar, Llc |
Hard surface cleaning composition
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
RS56419B1
(sr)
|
2010-12-03 |
2018-01-31 |
Biontech Rna Pharmaceuticals Gmbh |
Postupak za ćelijsku ekspresiju rnk
|
WO2012072096A1
(en)
|
2010-12-03 |
2012-06-07 |
Biontech Ag |
Method for cellular rna expression
|
AU2011338682B2
(en)
|
2010-12-06 |
2017-04-27 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising threose modifications
|
WO2012090150A2
(en)
|
2010-12-27 |
2012-07-05 |
Compugen Ltd |
New cell-penetrating peptides and uses thereof
|
DK3202760T3
(da)
|
2011-01-11 |
2019-11-25 |
Alnylam Pharmaceuticals Inc |
Pegylerede lipider og deres anvendelse til lægemiddelfremføring
|
US20140039034A1
(en)
|
2011-01-19 |
2014-02-06 |
Fumikazu SHINOHARA |
Composition for suppressing expression of target gene
|
AU2012212105A1
(en)
|
2011-02-03 |
2013-09-12 |
Mirna Therapeutics, Inc. |
Synthetic mimics of miR-124
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
EP2681315B1
(en)
|
2011-03-03 |
2017-05-03 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
US9205100B2
(en)
|
2011-03-03 |
2015-12-08 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
RU2017129844A
(ru)
|
2011-04-11 |
2019-02-06 |
Таргетед Гроус, Инк. |
Идентификация и применение мутантных krp у растений
|
CN107090043B
(zh)
|
2011-05-13 |
2021-12-07 |
加尼梅德药物公司 |
用于治疗表达密蛋白6之癌症的抗体
|
WO2012164058A1
(en)
|
2011-06-01 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for adjusting expression of mitochondrial genome by microrna
|
ES2690557T3
(es)
|
2011-06-02 |
2018-11-21 |
University Of Louisville Research Foundation, Inc. |
Nanopartículas conjugadas a un agente antinucleolina
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
AU2012267241B2
(en)
|
2011-06-10 |
2017-04-06 |
Temasek Life Sciences Laboratory Limited |
Genetic manipulation and expression systems for Pucciniomycotina and Ustilaginomycotina subphyla
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
EP2739645B1
(en)
|
2011-08-01 |
2018-12-19 |
Tufts Medical Center, Inc. |
Endoglin-specific antibody for use in a method of treating heart failure and related conditions
|
KR20140057374A
(ko)
|
2011-09-02 |
2014-05-12 |
노파르티스 아게 |
Hsf1-관련 질환을 치료하기 위한 유기 조성물
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
US9701623B2
(en)
|
2011-09-27 |
2017-07-11 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
US9249468B2
(en)
|
2011-10-14 |
2016-02-02 |
The Ohio State University |
Methods and materials related to ovarian cancer
|
EP3542851B1
(en)
|
2011-10-27 |
2021-12-15 |
Sorrento Therapeutics, Inc. |
Implantable devices for delivery of bioactive agents
|
US20170246439A9
(en)
|
2011-10-27 |
2017-08-31 |
Kimberly-Clark Worldwide, Inc. |
Increased Bioavailability of Transdermally Delivered Agents
|
EP2771482A1
(en)
|
2011-10-27 |
2014-09-03 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for the treatment and diagnosis of atherosclerosis
|
KR102145638B1
(ko)
|
2011-10-27 |
2020-08-18 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
고점도 생체활성 제제의 경피 전달 방법
|
MX356814B
(es)
|
2011-11-03 |
2018-06-13 |
Quark Pharmaceuticals Inc |
Métodos y composiciones para neuroprotección.
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
US20150126438A1
(en)
|
2012-01-24 |
2015-05-07 |
Beth Israel Deaconess Medical Center, Inc. |
Novel ChREBP Isoforms and Methods Using the Same
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
CN104428009A
(zh)
|
2012-02-07 |
2015-03-18 |
全球生物疗法美国有限公司 |
核酸输送的区室化方法及其组合物和应用
|
CA2863600A1
(en)
|
2012-02-16 |
2013-08-22 |
The Penn State Research Foundation |
Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
|
US9193971B2
(en)
|
2012-04-10 |
2015-11-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods for the treatment of nonalcoholic steatohepatitis
|
WO2013153139A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of acute leukemia
|
ES2655842T3
(es)
|
2012-04-18 |
2018-02-21 |
Cell Signaling Technology, Inc. |
EGFR y ROS1 en el cáncer
|
US20140108091A1
(en)
*
|
2012-04-19 |
2014-04-17 |
FullCircle CRM |
Method and System for Attributing Metrics in a CRM System
|
CN104797712B
(zh)
|
2012-04-19 |
2018-06-12 |
淡马锡生命科学研究院有限公司 |
提高棉纤维长度的方法
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
JP2015521041A
(ja)
|
2012-05-16 |
2015-07-27 |
サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Pkn3阻害剤投与のためのバイオマーカーとしてのvegfr1の使用
|
US9869519B2
(en)
*
|
2012-07-12 |
2018-01-16 |
Google Inc. |
Thermosiphon systems for electronic devices
|
AU2013291125A1
(en)
|
2012-07-16 |
2015-01-22 |
Dicerna Pharmaceuticals, Inc. |
RNAi pharmaceutical composition capable of suppressing expression of KRAS gene
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
WO2014071963A1
(en)
|
2012-11-09 |
2014-05-15 |
Biontech Ag |
Method for cellular rna expression
|
CA2890529C
(en)
|
2012-11-09 |
2020-07-28 |
Biontech Ag |
Method for modification of cellular rna expression comprising interferon (ifn) receptors and signalling
|
DK2920201T3
(da)
|
2012-11-15 |
2020-04-14 |
Apellis Pharmaceuticals Inc |
Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder
|
US10308687B2
(en)
|
2013-03-15 |
2019-06-04 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
EP2978446B1
(en)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antibody for use in treating alzheimer's disease
|
CN104211814A
(zh)
|
2013-05-29 |
2014-12-17 |
三星电子株式会社 |
用于消耗靶膜蛋白的组合物
|
SG10201805197VA
(en)
*
|
2013-06-19 |
2018-07-30 |
Apse Llc |
Compositions and methods using capsids resistant to hydrolases
|
EP3013424A4
(en)
|
2013-06-25 |
2017-03-29 |
University of Canberra |
Methods and compositions for modulating cancer stem cells
|
CA2918387C
(en)
|
2013-07-19 |
2021-11-02 |
Monsanto Technology Llc |
Compositions and methods for controlling leptinotarsa
|
EP3027223A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
WO2015015496A1
(en)
|
2013-07-31 |
2015-02-05 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
CA2920261C
(en)
|
2013-08-08 |
2018-04-03 |
Global Bio Therapeutics, Inc. |
Clamp device for minimally invasive procedures and uses thereof
|
AU2014310934B2
(en)
|
2013-08-21 |
2019-09-12 |
CureVac SE |
Respiratory syncytial virus (RSV) vaccine
|
ES2851724T3
(es)
|
2013-09-18 |
2021-09-08 |
Epiaxis Therapeutics Pty Ltd |
Modulación de células madre
|
US10077444B2
(en)
*
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
JP6946000B2
(ja)
|
2013-10-04 |
2021-10-06 |
アプトース バイオサイエンシーズ, インコーポレイテッド |
がんの治療用組成物及び方法
|
US10004814B2
(en)
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
RU2744194C2
(ru)
|
2013-12-02 |
2021-03-03 |
Фио Фармасьютикалс Корп |
Иммунотерапия рака
|
US10150965B2
(en)
|
2013-12-06 |
2018-12-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
WO2015086828A1
(en)
|
2013-12-12 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
|
CA2937118A1
(en)
|
2014-01-17 |
2015-07-23 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid capable of inhibiting expression of .beta.2gpi
|
WO2015136001A1
(en)
|
2014-03-11 |
2015-09-17 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
AU2015236215B2
(en)
|
2014-03-25 |
2020-03-19 |
Arcturus Therapeutics, Inc. |
UNA oligomers having reduced off-target effects in gene silencing
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
WO2015148582A1
(en)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Transthyretin allele selective una oligomers for gene silencing
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
CN106413390B
(zh)
|
2014-04-01 |
2019-09-27 |
孟山都技术公司 |
用于控制虫害的组合物和方法
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
LT3151859T
(lt)
|
2014-06-09 |
2021-03-25 |
Ultragenyx Pharmaceutical Inc. |
Veiksminga ir efektyvi serumo fosfatų kontrolė optimaliam kaulų formavimosi užtikrinimui
|
JP6264329B2
(ja)
|
2014-06-18 |
2018-01-24 |
トヨタ自動車株式会社 |
車両用駆動制御装置
|
WO2016018887A1
(en)
|
2014-07-29 |
2016-02-04 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
CA2958704A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
JP6836987B2
(ja)
|
2014-09-05 |
2021-03-03 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
Tyrまたはmmp1を標的とする核酸を用いて老化および皮膚障害を処置するための方法
|
EP3191592A1
(en)
|
2014-09-11 |
2017-07-19 |
Novartis AG |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
US11390885B2
(en)
|
2014-09-15 |
2022-07-19 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation
|
US20170296561A1
(en)
|
2014-09-25 |
2017-10-19 |
Cold Spring Harbor Laboratory |
Treatment of rett syndrome
|
AU2015330731B2
(en)
|
2014-10-10 |
2020-07-09 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using TLR9 agonist with checkpoint inhibitors
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
JP6930913B2
(ja)
|
2014-10-14 |
2021-09-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
炎症を阻害するためのcdk9及びbrd4阻害剤の使用法
|
WO2016062323A1
(en)
|
2014-10-20 |
2016-04-28 |
Biontech Ag |
Methods and compositions for diagnosis and treatment of cancer
|
SG11201703132UA
(en)
|
2014-10-22 |
2017-05-30 |
Temasek Life Sciences Lab Ltd |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
AU2015346281B2
(en)
|
2014-11-12 |
2021-12-02 |
Nmc, Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
CN107109407A
(zh)
|
2014-11-14 |
2017-08-29 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
US10479997B2
(en)
|
2014-12-01 |
2019-11-19 |
Novartis Ag |
Compositions and methods for diagnosis and treatment of prostate cancer
|
ES2754549T3
(es)
|
2014-12-03 |
2020-04-20 |
Glycomimetics Inc |
Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
|
US10968449B2
(en)
|
2015-01-22 |
2021-04-06 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
US10500273B2
(en)
|
2015-03-02 |
2019-12-10 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using an IL-33 antagonist
|
WO2016145005A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticles for brain tumor treatment
|
WO2016161299A1
(en)
|
2015-04-01 |
2016-10-06 |
Arcturus Therapeutics, Inc. |
Therapeutic una oligomers and uses thereof
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
WO2016179394A1
(en)
|
2015-05-05 |
2016-11-10 |
Malik Mohammad Tariq |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
US10933049B2
(en)
|
2015-06-03 |
2021-03-02 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
WO2016193945A2
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
US11001845B2
(en)
|
2015-07-06 |
2021-05-11 |
Phio Pharmaceuticals Corp. |
Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
MX2018002090A
(es)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
|
MX2018003096A
(es)
|
2015-09-15 |
2018-05-11 |
Samyang Biopharmaceuticals |
Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
|
EP3356415B1
(en)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
EP3359555B1
(en)
|
2015-10-07 |
2023-12-20 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens
|
EP3365446A4
(en)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
|
EP3391875B1
(en)
|
2015-12-18 |
2021-11-03 |
Samyang Holdings Corporation |
Method for preparing polymeric micelle containing anionic drug
|
US11856951B2
(en)
|
2015-12-22 |
2024-01-02 |
Provivi, Inc. |
Method for managing resistance to insecticidal traits and chemicals using pheromones
|
WO2017151708A1
(en)
|
2016-03-02 |
2017-09-08 |
Glycomimetics, Inc. |
Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
|
WO2017152073A1
(en)
|
2016-03-04 |
2017-09-08 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
|
UY37146A
(es)
|
2016-03-07 |
2017-09-29 |
Arrowhead Pharmaceuticals Inc |
Ligandos de direccionamiento para compuestos terapéuticos
|
CN109310885B
(zh)
|
2016-03-15 |
2022-05-31 |
梅尔莎纳医疗公司 |
NaPi2b靶向抗体-药物缀合物及其使用方法
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
US9988641B2
(en)
|
2016-04-05 |
2018-06-05 |
Corn Products Development, Inc. |
Compositions and methods for producing starch with novel functionality
|
EP3445850B1
(en)
|
2016-04-22 |
2021-10-27 |
BioNTech SE |
Methods for providing single-stranded rna
|
ES2941502T3
(es)
|
2016-05-13 |
2023-05-23 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
|
CA3024449A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
CN110214187B
(zh)
|
2016-05-18 |
2024-01-30 |
沃雅戈治疗公司 |
调节性多核苷酸
|
PT109454A
(pt)
|
2016-06-14 |
2017-12-14 |
Phyzat Biopharmaceuticals Lda |
Ácidos nucleicos de interferência e composições que os compreendem
|
BR112019000015A2
(pt)
|
2016-06-30 |
2019-04-24 |
Oncorus, Inc. |
distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
|
EP3519582A1
(en)
|
2016-07-29 |
2019-08-07 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
US11433086B2
(en)
|
2016-08-08 |
2022-09-06 |
Glycomimetics, Inc. |
Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
|
KR20230115344A
(ko)
|
2016-09-02 |
2023-08-02 |
애로우헤드 파마슈티컬스 인코포레이티드 |
표적화 리간드
|
US10933081B2
(en)
|
2016-09-21 |
2021-03-02 |
Alnylam Pharmaceuticals, Inc. |
Myostatin iRNA compositions and methods of use thereof
|
AU2017341065B2
(en)
|
2016-10-07 |
2023-04-06 |
Glycomimetics, Inc. |
Highly potent multimeric E-selectin antagonists
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
KR20190098748A
(ko)
|
2017-01-10 |
2019-08-22 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법
|
JP7215716B2
(ja)
|
2017-01-13 |
2023-01-31 |
学校法人自治医科大学 |
肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのaavベクター
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
JPWO2018164186A1
(ja)
|
2017-03-09 |
2020-01-09 |
協和キリン株式会社 |
Masp2の発現を抑制する核酸
|
CA3054605A1
(en)
|
2017-03-15 |
2018-09-20 |
Glycomimetics, Inc. |
Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
|
JPWO2018186032A1
(ja)
|
2017-04-05 |
2020-02-13 |
国立大学法人千葉大学 |
Swi/snf複合体の機能阻害剤
|
KR20190139931A
(ko)
|
2017-04-07 |
2019-12-18 |
아펠리스 파마슈티컬스 인코포레이티드 |
투여 요법 및 관련 조성물 및 방법
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
CN106973864A
(zh)
*
|
2017-04-25 |
2017-07-25 |
遵义医学院 |
一种适用于白背飞虱注射法rna干扰实验的饲养装置及其使用方法
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
AU2018277476A1
(en)
|
2017-05-31 |
2020-01-02 |
Kyowa Kirin Co., Ltd. |
APCS-expression-suppressing nucleic acids
|
EP4085919A3
(en)
|
2017-07-21 |
2023-02-08 |
Novartis AG |
Compositions and methods to treat cancer
|
FI3684423T3
(fi)
|
2017-09-20 |
2023-06-15 |
4D Molecular Therapeutics Inc |
Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Sod1二重発現ベクターおよびその使用
|
AU2018352236A1
(en)
|
2017-10-16 |
2020-04-23 |
The Curators Of The University Of Missouri |
Treatment of amyotrophic lateral sclerosis (ALS)
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
SG11202003488WA
(en)
|
2017-10-20 |
2020-05-28 |
Dicerna Pharmaceuticals Inc |
Methods for treating hepatitis b infection
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
PE20210915A1
(es)
|
2017-11-27 |
2021-05-19 |
4D Molecular Therapeutics Inc |
Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis
|
WO2019108750A1
(en)
|
2017-11-30 |
2019-06-06 |
Glycomimetics, Inc. |
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
MX2020005860A
(es)
|
2017-12-06 |
2020-09-09 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica.
|
JP2021506883A
(ja)
|
2017-12-21 |
2021-02-22 |
メルサナ セラピューティクス インコーポレイテッド |
ピロロベンゾジアゼピン抗体結合体
|
AU2018395417B2
(en)
|
2017-12-29 |
2023-07-13 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
AU2019209324A1
(en)
|
2018-01-16 |
2020-07-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting ALDH2 expression
|
EP3761994A1
(en)
|
2018-03-05 |
2021-01-13 |
GlycoMimetics, Inc. |
Methods for treating acute myeloid leukemia and related conditions
|
WO2019213276A1
(en)
|
2018-05-02 |
2019-11-07 |
Novartis Ag |
Regulators of human pluripotent stem cells and uses thereof
|
WO2020026968A1
(ja)
|
2018-07-30 |
2020-02-06 |
株式会社遺伝子治療研究所 |
Aavベクターによる遺伝子発現を増強する方法
|
EA202190528A1
(ru)
|
2018-08-13 |
2021-04-23 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
KR20210132661A
(ko)
|
2019-02-12 |
2021-11-04 |
다이서나 파마수이티컬, 인크. |
Cyp27a1의 발현을 억제하기 위한 방법 및 조성물
|
US20220170025A1
(en)
|
2019-04-04 |
2022-06-02 |
Dicerna Pharmaceuticals Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
JP2022529917A
(ja)
|
2019-04-18 |
2022-06-27 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンの処置及び予後のための方法
|
CN114761558A
(zh)
*
|
2019-07-02 |
2022-07-15 |
株式会社Na疫苗研究所 |
新型核糖核酸和基于其的药物组合物
|
JP7371954B2
(ja)
|
2019-07-12 |
2023-10-31 |
株式会社遺伝子治療研究所 |
ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
CA3163490A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffman-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
WO2021130270A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
CN116096889A
(zh)
|
2020-03-18 |
2023-05-09 |
迪克纳制药公司 |
用于抑制angptl3表达的组合物和方法
|
AU2021237465A1
(en)
|
2020-03-19 |
2022-10-13 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
CA3176356A1
(en)
|
2020-04-22 |
2021-10-28 |
Anne BROOKS |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
US20210332364A1
(en)
|
2020-04-28 |
2021-10-28 |
Phyzat Biopharmaceuticals, Lda |
siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
|
US20210348167A1
(en)
|
2020-05-09 |
2021-11-11 |
Phyzat Biopharmaceuticals, Lda |
siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
|
CN115702243A
(zh)
|
2020-06-09 |
2023-02-14 |
罗氏创新中心哥本哈根有限公司 |
用于治疗性多核苷酸的鸟苷类似物
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
KR20230061389A
(ko)
|
2020-08-04 |
2023-05-08 |
다이서나 파마수이티컬, 인크. |
올리고뉴클레오티드의 전신 전달
|
CA3190794A1
(en)
|
2020-08-05 |
2022-02-10 |
Soren Ottosen |
Oligonucleotide treatment of hepatitis b patients
|
CA3185348A1
(en)
|
2020-08-05 |
2022-02-10 |
Bob Dale Brown |
Compositions and methods for inhibiting lpa expression
|
EP4247952A2
(en)
|
2020-11-23 |
2023-09-27 |
Phyzat Biopharmaceuticals, Lda. |
Sina molecules, methods of production and uses thereof
|
JP2023553343A
(ja)
|
2020-11-25 |
2023-12-21 |
アカゲラ・メディスンズ,インコーポレイテッド |
核酸を送達するための脂質ナノ粒子および関連する使用方法
|
CN112511569B
(zh)
*
|
2021-02-07 |
2021-05-11 |
杭州筋斗腾云科技有限公司 |
网络资源访问请求的处理方法、系统及计算机设备
|
BR112023017367A2
(pt)
|
2021-04-12 |
2023-12-12 |
Boehringer Ingelheim Int |
Composições e métodos para inibição de ceto-hexoquinase (khk)
|
CA3215103A1
(en)
|
2021-04-12 |
2022-10-20 |
Steffen Panzner |
Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
|
AR125351A1
(es)
|
2021-04-14 |
2023-07-12 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión de pnpla3
|
KR102644654B1
(ko)
|
2021-04-19 |
2024-03-07 |
노보 노르디스크 에이/에스 |
핵 수용체 서브패밀리 1 그룹 h 구성원 3(nr1h3) 발현을 억제하기 위한 조성물 및 방법
|
JPWO2022224372A1
(ja)
|
2021-04-21 |
2022-10-27 |
|
|
JP7463621B2
(ja)
|
2021-05-28 |
2024-04-08 |
ノヴォ ノルディスク アー/エス |
ミトコンドリアアミドキシム還元成分1(marc1)発現を阻害するための組成物および方法
|
EP4349852A1
(en)
|
2021-05-28 |
2024-04-10 |
Shanghai Regenelead Therapies Co., Ltd. |
Recombinant adeno-associated virus having variant capsid, and application thereof
|
US20230107967A1
(en)
|
2021-08-25 |
2023-04-06 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting alpha-1 antitrypsin expression
|
WO2023083906A2
(en)
|
2021-11-11 |
2023-05-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
AU2022402155A1
(en)
|
2021-12-01 |
2024-05-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating apoc3 expression
|
WO2023118546A2
(en)
|
2021-12-23 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
|
WO2023193892A1
(en)
|
2022-04-05 |
2023-10-12 |
BioNTech SE |
Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
|
US20230374522A1
(en)
|
2022-04-15 |
2023-11-23 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating scap activity
|
US20230416742A1
(en)
|
2022-05-12 |
2023-12-28 |
Dicerna Phrmaceuticals, Inc. |
Compositions and methods for inhibiting mapt expression
|
US20230416743A1
(en)
|
2022-05-13 |
2023-12-28 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting snca expression
|
TW202400193A
(zh)
|
2022-06-24 |
2024-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
|
WO2024028325A1
(en)
|
2022-08-01 |
2024-02-08 |
BioNTech SE |
Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
|